Expression Table for this CRE
| SRX6586360 | CNhi10331_MCF-7_siRNA (HSS104864) treatment-48h_rep3 | 200.6 |
| SRX6586361 | CNhi10331_MCF-7_siRNA (HSS179267) treatment-48h_rep1 | 180.0 |
| SRX9760368 | skeletal muscle_6_h_after_exercise (Individual 7) | 175.6 |
| SRX6586362 | CNhi10331_MCF-7_siRNA (HSS179267) treatment-48h_rep2 | 141.3 |
| CNhs10610 | SABiosciences XpressRef Human Universal Total RNA, pool1 | 107.0 |
| SRX9760348 | skeletal muscle_prior_exercise (Individual 7) | 101.6 |
| SRX6586357 | CNhi10330_MCF-7_siRNA-negative control-48h_rep5 | 101.5 |
| SRX6586338 | CNhi10317_MCF-7_Rosuvastatin-30 uM-6h_rep3 | 100.7 |
| SRX9760364 | skeletal muscle_6_h_after_exercise (Individual 3) | 99.3 |
| SRX9760365 | skeletal muscle_prior_exercise (Individual 4) | 98.3 |
| CNhs11834 | carcinoid cell line:NCI-H1770 | 96.9 |
| SRX9760357 | skeletal muscle_1_h_after_exercise (Individual 2) | 96.8 |
| CNhs14055 | iPS differentiation to neuron, control donor C32-CRL1502, day18, rep3 | 96.0 |
| SRX6586342 | CNhi10318_MCF-7_Non-treatment (DMSO)-48h_rep6 | 89.9 |
| SRX9760356 | skeletal muscle_2_min_after_exercise (Individual 2) | 88.3 |
| SRX6586336 | CNhi10317_MCF-7_Rosuvastatin-30 uM-6h_rep1 | 84.1 |
| SRX9760367 | skeletal muscle_1_h_after_exercise (Individual 4) | 82.7 |
| CNhs13092 | mesenchymal precursor cell - ovarian cancer left ovary, donor2 | 82.7 |
| CNhs12092 | Hepatic Sinusoidal Endothelial Cells, donor2 | 82.7 |
| CNhs10617 | brain, adult, pool1 | 82.6 |
| SRX6586358 | CNhi10330_MCF-7_siRNA-negative control-48h_rep6 | 78.2 |
| SRX6586245 | CNhi10328_THP-1_Non-treatment (DMSO)-48h_rep5 | 75.4 |
| CNhs13922 | iPS differentiation to neuron, down-syndrome donor C18-CCL54, day18, rep2 | 74.9 |
| CNhs14065 | iPS differentiation to neuron, down-syndrome donor C18-CCL54, day12, rep3 | 74.3 |
| CNhs10608 | Clontech Human Universal Reference Total RNA, pool1 | 73.3 |
| SRX6586337 | CNhi10317_MCF-7_Rosuvastatin-30 uM-6h_rep2 | 72.5 |
| SRX6586347 | CNhi10319_MCF-7_Fluvastatin-30 uM-48h_rep2 | 71.3 |
| SRX6586244 | CNhi10328_THP-1_Non-treatment (DMSO)-48h_rep4 | 71.3 |
| CNhs14058 | iPS differentiation to neuron, down-syndrome donor C11-CCL54, day12, rep3 | 70.8 |
| CNhs11923 | Chondrocyte - de diff, donor1 | 70.5 |
| SRX9760358 | skeletal muscle_3_h_after_exercise (Individual 2) | 68.4 |
| SRX9760359 | skeletal muscle_6_h_after_exercise (Individual 2) | 65.7 |
| SRX6586339 | CNhi10318_MCF-7_Atrovastatin-30 uM-48h_rep1 | 65.6 |
| SRX6586346 | CNhi10319_MCF-7_Fluvastatin-30 uM-48h_rep1 | 65.2 |
| SRX6586359 | CNhi10331_MCF-7_siRNA (HSS104864) treatment-48h_rep2 | 65.0 |
| CNhs13851 | Myoblast differentiation to myotubes, day04, control donor1 | 64.8 |
| CNhs13513 | CD4+CD25+CD45RA+ naive regulatory T cells, donor3 | 62.3 |
| SRX6586344 | CNhi10318_MCF-7_Simvastatin-30 uM-48h_rep2 | 61.8 |
| SRX4504766 | human NET-CAGE GM12878, biol_rep1 | 61.7 |
| SRX9760350 | skeletal muscle_1_h_after_exercise (Individual 7) | 60.9 |
| SRX12709139 | Heart (Sample 23); the left and right atrial free wall, right and left ventricular base, and inferior and superior sinoatrial node | 60.8 |
| SRX6586352 | CNhi10330_MCF-7_siRNA (HSS104864) treatment-48h_rep1 | 60.5 |
| CNhs13854 | Myoblast differentiation to myotubes, day10, control donor1 | 60.0 |
| CNhs11918 | Saos-2 osteosarcoma treated with ascorbic acid and BGP to induce calcification, 00hr00min, biol_rep2 (A1 T0) | 59.8 |
| SRX12709142 | Heart (Sample 26); the left and right atrial free wall, right and left ventricular base, and inferior and superior sinoatrial node | 59.2 |
| CNhs13966 | H1 embryonic stem cells differentiation to CD34+ HSC, day03, biol_rep2 | 58.4 |
| SRX12709145 | Heart (Sample 29); the left and right atrial free wall, right and left ventricular base, and inferior and superior sinoatrial node | 58.0 |
| CNhs10616 | bladder, adult, pool1 | 56.7 |
| SRX6586242 | CNhi10328_THP-1_Atrovastatin-30 uM-48h_rep3 | 56.5 |
| SRX9760351 | skeletal muscle_3_h_after_exercise (Individual 7) | 56.5 |